Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Open access
Fehniger, Todd A., Larson, Sarah, Trinkaus, Kathryn, Siegel, Marilyn J., Cashen, Amanda F., Blum, Kristie A., Fenske, Timothy S., Hurd, David D., Goy, Andre, Schneider, Stephanie E., Keppel, Catherine R., Wagner-Johnston, Nina D., Carson, Kenneth R., Bartlett, Nancy L.·2011·Blood

Abstract

Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel/ref cHL patients was evaluated at a dose of 25 mg/d on days 1-21 of a 28-day cycle. Patients remained on lenalidomide until disease progression or an unacceptable adverse event (AE) occurred. Thirty-eight cHL patients were enrolled with a median of 4 (range, 2-9) prior therapies; 87% had undergone prior stem cell transplantation and 55% of patients did not respond to their last prior therapy. Of 36 evaluable patients, responses were 1 complete remission (CR), 6 partial remissions (PRs), and 5 patients with stable disease (SD) for ≥ 6 months resulting in an International Working Committee (IWC) objective overall response rate (ORR) of 19% and a cytostatic ORR of 33%. Decreased chemokine (CCL17 and CCL22) plasma levels at 2 weeks were associated with a subsequent response. The treatment was well tolerated, and the most common grade 3/4 AEs were neutropenia (47%), anemia (29%), and thrombocytopenia (18%). Four patients discontinued lenalidomide because of rash, elevated transaminases/bilirubin, and cytopenias. We provide preliminary evidence of lenalidomide's activity in patients with rel/ref cHL, and therefore exploration of lenalidomide in combination with other active agents is warranted. This trial is registered at www.ClinicalTrials.gov as NCT00540007.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-07-362475

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 191

Metadata

Authors
Fehniger, T. A., Larson, S., Trinkaus, K., Siegel, M. J., Cashen, A. F., Blum, K. A., Fenske, T. S., Hurd, D. D., Goy, A., Schneider, S. E., Keppel, C. R., Wagner-Johnston, N. D., Carson, K. R., & Bartlett, N. L.
Venue
Blood
Published
2011-11-10
Volume
118
Issue
19
Pages
5119-5125
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2017144533
Cited by
191
References
2
FWCI
10.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2011-07-362475
The paper
Fehniger, T. A., Larson, S., Trinkaus, K., Siegel, M. J., Cashen, A. F., Blum, K. A., Fenske, T. S., Hurd, D. D., Goy, A., Schneider, S. E., Keppel, C. R., Wagner-Johnston, N. D., Carson, K. R., & Bartlett, N. L. (2011). A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2011-07-362475

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.